PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35154461-0	2022	Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma.	Sorafenib	68-77	ATP citrate lyase	Homo sapiens	23-27	
35154461-11	2022	ACLY expression was higher in sorafenib-resistant cells and HCC-cell sensitivity to sorafenib increased after ACLY-knockout.	Sorafenib	30-39	ATP citrate lyase	Homo sapiens	0-4	
35154461-11	2022	ACLY expression was higher in sorafenib-resistant cells and HCC-cell sensitivity to sorafenib increased after ACLY-knockout.	Sorafenib	84-93	ATP citrate lyase	Homo sapiens	110-114	
35154461-14	2022	These data suggest that ACLY downregulation can reverse sorafenib resistance, and that SS-PEI can be used to mediate shRNA-ACLY transfection in HCC treatment.	Sorafenib	56-65	ATP citrate lyase	Homo sapiens	24-28